Ascendia

  MARKET NEWS

ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-Proof Antibody Against the SARS-CoV-2 Variant JN.1
Kindeva Expands Facilities to Support Growth of Green Propellant Commercialization
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients With Tenosynovial Giant Cell Tumor
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
Ecolab Life Sciences & Repligen Announce Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
uniQure Receives FDA Regenerative Medicine Advanced Therapy Designation for Investigational Gene Therapy in Huntington’s Disease

  FEATURED EDITORIAL

  COMPANY PROFILE

With 27 plants on four continents, Datwyler has a global production footprint with its own elastomer mixing plants and mould shops. For us, a global strategic approach with a local/regional presence is a key success factor. Our manufacturing set-up guarantees identical quality standards on a global level while providing local-for-local manufacturing capacities and technical support. This enables us to meet our customers’ needs for flexible and reliable supply chains in order to ensure business continuity. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Biolojic Design Enters Multi-Target Drug Discovery Collaboration With Merck KGaA

Biolojic Design Enters Multi-Target Drug Discovery Collaboration With Merck KGaA

Merck KGaA, Darmstadt, Germany, will leverage Biolojic Design’s AI capabilities to create potential best-in-class multi-specific antibodies that uniquely modulate biology….

Longeveron Announces Contract Development & Manufacturing Business & First Contract

Longeveron Announces Contract Development & Manufacturing Business & First Contract

Longeveron Inc. recently announced the launch of its contract development and manufacturing business at the company’s 15,000-sq-ft state-of-the-art Good Manufacturing Practice (GMP) facility. This facility contains….

Aeterna Zentaris & Ceapro Complete Merger Transaction

Aeterna Zentaris & Ceapro Complete Merger Transaction

Aeterna Zentaris Inc. and Ceapro Inc. recently announce the successful completion and closing of their all-stock merger of equals transaction (the Transaction), which was previously announced by….

Jeito Capital Announces Acquisition by Merck & Co. of its Portfolio Company EyeBio for a Potential Value of  Billion

Jeito Capital Announces Acquisition by Merck & Co. of its Portfolio Company EyeBio for a Potential Value of $3 Billion

This acquisition reflects the significant clinical progress achieved with Restoret, EyeBio’s novel late-phase candidate for diabetic macular edema, as well as….

  WHITEPAPERS & WEBINARS

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations suitable for subcutaneous (subQ) injection. SubQ application of highly concentrated protein formulations enables a higher patient convenience and might thus lead to reduction in health costs. …

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.

Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared

…

WHITEPAPER - Continuous Flow - An Emerging Alternative

WHITEPAPER - Continuous Flow - An Emerging Alternative

Pharmaceutical companies have traditionally been risk-averse, often adopting safe and well-established processes due to the conservative stance of regulatory agencies on novel methodologies. However, with the increasing complexity of drug molecules and the demand for newer and harsher reaction conditions, …

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.

Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 12 – Inhalation Delivery
June 19 – Bioavailability